{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"113"},{"groupId":"OG001","value":"127"},{"comment":"Minimum and maximum data values cannot be reported; doing so for the small sample size could lead to the re-identification of participants.","groupId":"OG002","value":"NA"},{"comment":"Minimum and maximum data values cannot be reported; doing so for the small sample size could lead to the re-identification of participants.","groupId":"OG003","value":"NA"},{"comment":"Minimum and maximum data values cannot be reported; doing so for the small sample size could lead to the re-identification of participants.","groupId":"OG004","value":"NA"}]}],"title":"Minimum value, uncensored"},{"categories":[{"measurements":[{"groupId":"OG000","value":"766"},{"groupId":"OG001","value":"604"},{"comment":"Minimum and maximum data values cannot be reported; doing so for the small sample size could lead to the re-identification of participants.","groupId":"OG002","value":"NA"},{"comment":"Minimum and maximum data values cannot be reported; doing so for the small sample size could lead to the re-identification of participants.","groupId":"OG003","value":"NA"},{"comment":"Minimum and maximum data values cannot be reported; doing so for the small sample size could lead to the re-identification of participants.","groupId":"OG004","value":"NA"}]}],"title":"Maximum value, uncensored"}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"1"}],"units":"Participants"}],"description":"Overall survival was defined as the time from the first dose of study drug to death from any cause until study completion.","groups":[{"description":"In Phase 1, participants received oral INCB001158 75 milligrams (mg) twice daily (BID) in 28-day cycles starting at Cycle 1, and 1800 mg subcutaneous daratumumab, administered once weekly for Cycles 1 and 2, once every 2 weeks for Cycles 3 to 6, and once every 4 weeks thereafter. Treatment continued until disease progression, unacceptable toxicity, or discontinuation from study treatment for any other reason.","id":"OG000","title":"Phase 1: INCB001158 75 mg BID + Daratumumab"},{"description":"In Phase 1, participants received oral INCB001158 100 mg BID in 28-day cycles starting at Cycle 1, and 1800 mg subcutaneous daratumumab, administered once weekly for Cycles 1 and 2, once every 2 weeks for Cycles 3 to 6, and once every 4 weeks thereafter. Treatment continued until disease progression, unacceptable toxicity, or discontinuation from study treatment for any other reason.","id":"OG001","title":"Phase 1: INCB001158 100 mg BID + Daratumumab"},{"description":"In Phase 1, participants received oral INCB001158 100 mg BID in 28-day cycles starting at Cycle 1, and 1800 mg subcutaneous daratumumab, administered once weekly for Cycles 1 and 2, once every 2 weeks for Cycles 3 to 6, and once every 4 weeks thereafter. Treatment continued until disease progression, unacceptable toxicity, or discontinuation from study treatment for any other reason.","id":"OG002","title":"Phase 2: INCB001158 100 mg BID + Daratumumab"},{"description":"In Part 1 of Phase 2, participants received daratumumb 1800 mg subcutaneous daratumumab, administered once weekly for Cycles 1 and 2 (28-day cycles), once every 2 weeks for Cycles 3 to 6, and once every 4 weeks thereafter. At the time of confirmed disease progression, participants crossed over to Part 2 of Phase 2 to receive oral INCB001158 100 mg BID starting at Cycle 1, and 1800 mg subcutaneous daratumumab, administered once weekly for Cycles 1 and 2, once every 2 weeks for Cycles 3 to 6, and once every 4 weeks thereafter. Treatment in Phase 2 continued for as long as participants were receiving clinical benefit and did not met any criteria for study withdrawal.","id":"OG003","title":"Phase 2: Daratumumab Monotherapy; Cross Over to INCB001158 + Daratumumab"},{"description":"In Part 1 of Phase 2, participants received oral INCB001158 100 mg BID in 28-day cycles starting at Cycle 1. At the time of confirmed disease progression, participants crossed over to Part 2 of Part 2 to receive oral INCB001158 100 mg BID starting at Cycle 1, and 1800 mg subcutaneous daratumumab, administered once weekly for Cycles 1 and 2, once every 2 weeks for Cycles 3 to 6, and once every 4 weeks thereafter. Treatment in Phase 2 continued for as long as participants were receiving clinical benefit and did not met any criteria for study withdrawal.","id":"OG004","title":"Phase 2: INCB001158 Monotherapy; Cross Over to INCB001158 + Daratumumab"}],"paramType":"NUMBER","populationDescription":"Full Analysis Population. As a result of an early-termination decision following a recruitment challenge (no safety-related concerns), a formal analysis was not performed due to an insufficient number of participants enrolled in Phase 2. Overall survival was calculated for individual participants, but data were not formally analyzed.","reportingStatus":"POSTED","timeFrame":"up to 923 days (approximately 2.5 years)","title":"Overall Survival","type":"SECONDARY","unitOfMeasure":"days"}